LBP and cancer: Despite these limitations, our study identifies Enterococcus lactis MNC-168 as a novel LBP for cancer immunotherapy and advances our understanding of microbiota-mediated regulation of antitumor immunity, offering potential avenues for enhancing therapeutic efficacy.